PharmAust: Gets approval to increase dosage in MPL trial

PharmAust (PAA) has received the green light from the trial safety committee to increase the tablet dosage in its motor neurone disease study
The company reported no safety issues or serious adverse events found during its study, as a result of the treatment
The company says it will continue supplying MPL tablets to all six patients in cohort one, with a four-week escalating dose of the MPL tablets set to begin
Patient recruitment for the next stage MPL dosing level has started, with four new patients currently undergoing screening
The company shares were up 1.15 per cent, trading at 8.8 cents at 1:15 pm AEDT

January 20, 2023